TRI
TRIVARX LTD
$0.0100
0.00%
Market cap
$12M
Turnover
$12,943
Last price
$0.0100
Day change
0.00%
Announcements
9
Range, past year
Open 0.012 · Low 0.007 · Now 0.010 · High 0.035
Open TRI in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
TRI momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-10-13.
Momentum quality
34/100
Wyckoff phase
Accumulation8d
Trend stage
Neutral
1 Day
+0.0%
1 Week
+0.0%
1 Month
-16.7%
1 Year
-16.7%
RSI
37
Avg daily range
8.7%
TRIVARX LTD scores 34 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.
On the Wyckoff cycle it sits in Accumulation, where it has been for 8 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
What stands out
- Trend R² 0.85 — highly linear uptrend
Points to watch
- 60d drawdown -52.6%
- High volatility (ATR 8.7%)
- Thin liquidity
- Risk rating: Very High
- Composite downside risk elevated
TRI announcements
Recent price-sensitive releases.
- 2026-09-23 Stabl-Im Clinical Development Update Progress Report
- 2026-08-27 Appendix 4E - Preliminary Final Report Preliminary Final Report
- 2026-07-28 June 2026 Quarterly Activities Report and Appendix 4C Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-07-16 Stabl-Im clinical trial supply milestone achieved
- 2026-05-22 CRO Engaged to Advance Stabl-Im Phase 1 Trial
- 2026-04-30 March 2026 Quarterly Activities Report and Appendix 4C
- 2026-04-29 Dr Danielle Meyrick appointed as CEO
More Health Care stocks
Most traded in the same sector.